We desire talent to come here, but are we genuinely welcoming them?

Sweden faces significant challenges in creating a truly inclusive environment that makes international professionals feel welcome, valued, and able to build mea...

Pharma Outsourcing – Find the Right Partner (2026)

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

Fem saker du måste veta om AI 2023

Är ditt jobb hotat av maskininlärning? Varför är det viktigt att hänga med i utvecklingen inom artificiell intelligens? Här får du svar på vad du behöver veta om AI just nu.

Petter Hartman: ”Existentiell egenvård i en kaotisk värld”

”Vår förmåga att möta livets svårigheter tycks hänga ihop med känslan av gemenskap och meningsfullhet”, skriver Petter Hartman i en krönika som tar upp regering...

Heidi Stensmyren is eager for new challenges in the biotech industry

Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Dir...

Galderma

Small robots to deliver pharmaceuticals to the body

Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list t...

TECHNIA AB

A green nursery for biotech rooted in the Scanian soil

Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders...

Höstens mest lästa krönikor

Här nedan läser du de mest lästa krönikorna i Life Science Sweden och systertidningen Medtech Magazine från hösten och vintern.

A new giant among our microscopes

Two technologies in one machine.

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

Partial court victory for entrepreneur who lost his company

Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...

Large study on milk: Risky for women but not for men

The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...

A new scientific event in Gothenburg

Life Science Sweden is holding an event in Gothenburg for the first time.

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Career coach on salaries: “There is no right or wrong”

What is a reasonable salary for my job? It's a question we all ask ourselves. But how important is a higher salary really? Career coach Tina Persson believes th...

Patentutgångar tvingar BMS till nytt sparpaket

Läkemedelsjätten Bristol Myers Squibb planerar nya stora nedskärningar mindre än ett år efter det förra sparpaketet.

RFK Jr: I september vet vi vad som orsakar autism

USA ska identifiera orsaken till autism – och det ska vara gjort till september i år. Det säger USA:s hälsominister Robert F. Kennedy Jr., som därmed sätter en ...

KI-forskare har upptäckt biomarkörer för postcovid

Forskare vid Karolinska institutet har i en ny studie identifierat en uppsättning proteiner i blod hos personer med långvariga besvär av postcovid.

Scale Up Your Image Analysis

ZEISS arivis Hub for accelerated analysis and faster results.